Biotechnology
Gene Solutions Makes Earlier Detection of Cancer A Possibility of the Future
HO CHI MINH CITY, Vietnam, March 16, 2022 /PRNewswire/ -- The scientific
research team fromGene Solutions
2022-03-16 09:36
3157
European Wellness Biomedical Group and AK International to Bring Biological Regenerative Medicine Solutions to Pakistan and UAE
DUBAI, UAE, March 15, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has signed a Memorandum of Agreement (MOA) withDubai-based AK International LLC (AKI), partnering together to undertake a number of joint venture businesses inPakistan and the MENA region that focus on providing ...
2022-03-15 08:00
2842
Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan
TOKYO, March 14, 2022 /PRNewswire/ -- The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardan...
2022-03-14 16:22
2240
Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology related deals dominate the landscape Biotech companies in U.S. awarded largest sums of capital, followed by Mainland China and UK LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in provid...
2022-03-14 16:00
2075
CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer
* GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved inChina for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC) * The labeled indications of GAVRETO have been expanded after it was approved by...
2022-03-14 08:05
2880
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
SHANGHAI, March 14, 2022 /PRNewswire/ -- Everest Medicines
2022-03-14 08:00
3010
Terran Biosciences announces acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals
NEW YORK, March 11, 2022 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio...
2022-03-11 21:38
7417
NMPA Clears IND for First T-Cell Receptor (TCR) T Cell Therapy to Treat Hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC)
SINGAPORE, March 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG"), a leading biotechnology company, today announced that the China National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for SCG101, the company's first T-...
2022-03-11 21:07
4887
Novavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...
2022-03-10 22:00
3497
Everlife acquires Research Instruments Group and other laboratory suppliers to boost presence in strategic life sciences and clinical diagnostics segments in South East Asia
SINGAPORE, March 10, 2022 /PRNewswire/ -- Everlife Holdings Pte Ltd ("Everlife"), a leading market access and distribution company inIndia and South East Asia, has announced the completion of its acquisition of Research Instruments Group ("RI"), a leading provider of scientific and laboratory in...
2022-03-10 12:00
3282
Nature Research Custom Media: SHAPING THE FUTURE OF OMICS FOR ALL
SHENZHEN, China, March 10, 2022 /PRNewswire/ -- Nature Research Custom Media published a feature story "Shaping the Future of Omics for All" about BGI Genomics, showcasing how the world-leading genome sequencing organization cultivates and leads the gene sequencing service industry and brings ...
2022-03-10 10:05
2352
Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
- The novel bispecific antibody ATG-101 is Antengene's first in house developed molecule with global rights. - This approval in China marks the third regulatory clearance granted to ATG-101 globally. - Upon receiving clearances in Australia and the U.S. in 2021, the Phase I study of ATG-101 ...
2022-03-10 08:52
2467
Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
SUZHOU, China, March 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta has ...
2022-03-10 08:30
3192
Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis
- Cystinosis is a rare genetic disease affecting 1 in 100,000-200,000 live births and poses a lifelong risk to those affected. Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain. - There are currently no curative treatme...
2022-03-10 00:57
2230
SOPHiA GENETICS HRD Solution Adopted in Asia Pacific
BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies inTaiwan aiming to provide genetic testing to clinicians, is the first institution inAsia...
2022-03-09 21:57
2143
NCCN Expands Resources for Treating Rare Cancer Types
The National Comprehensive Cancer Network publishes two new NCCN Guidelines for Malignant Peritoneal Mesothelioma and for Ampullary Adenocarcinoma, to standardize treatment and improve outcomes for these rare tumor types; also reaches milestone expanding library of NCCN Chemotherapy Order Templat...
2022-03-09 21:56
1516
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
* Posters Showcase Early-Stage Clinical and Preclinical Pipeline. * Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, March 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company ...
2022-03-09 20:00
2490
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. ...
2022-03-09 19:08
2382
FIRST SURGERIES COMPLETED WITH PATIENT-SPECIFIC 3D PRINTED IMPLANTS PRODUCED AT THE LIMACORPORATE PROMADE POINT OF CARE CENTER AT HOSPITAL FOR SPECIAL SURGERY
UDINE, Italy, March 9, 2022 /PRNewswire/ -- LimaCorporate S.p.A., leading global orthopedics manufacturer, and Hospital for Special Surgery (HSS), consistently ranked number one in orthopedics globally by Newsweek and nationally byU.S. News & World Report in the U.S., today announced a new miles...
2022-03-09 06:16
1799
Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space
NEW YORK, March 9, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran") has entered into an agreement with theUniversity of Maryland, Baltimore ("UMB") for a worldwide exclusive license to develop and commercialize a portfolio of UMB's patents and data to support a novel approach to the treat...
2022-03-09 06:10
2731
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 350 media titles]
2024-09-18 11:30
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
[Picked up by 284 media titles]
2024-09-14 17:37
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
[Picked up by 283 media titles]
2024-09-19 14:00
Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
[Picked up by 274 media titles]
2024-09-19 08:00
Most Read
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
2024-09-14 17:37
9912
Maiji Mountain Grottoes: Carved in stone, evolving in time
2024-09-14 13:23
8347
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
2024-09-16 11:50
8265
Vision China: US, China urged to find right path in ties
2024-09-14 01:10
7843
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
2024-09-18 11:30
6827